[go: up one dir, main page]

AU2001274817A1 - Agents that modulate dna-pk activity and methods of use thereof - Google Patents

Agents that modulate dna-pk activity and methods of use thereof

Info

Publication number
AU2001274817A1
AU2001274817A1 AU2001274817A AU7481701A AU2001274817A1 AU 2001274817 A1 AU2001274817 A1 AU 2001274817A1 AU 2001274817 A AU2001274817 A AU 2001274817A AU 7481701 A AU7481701 A AU 7481701A AU 2001274817 A1 AU2001274817 A1 AU 2001274817A1
Authority
AU
Australia
Prior art keywords
agents
activity
methods
modulate dna
modulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001274817A
Inventor
Augusto F. Lois
Eyal Raz
Kenji Takabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU2001274817A1 publication Critical patent/AU2001274817A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001274817A 2000-05-05 2001-05-04 Agents that modulate dna-pk activity and methods of use thereof Abandoned AU2001274817A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20227400P 2000-05-05 2000-05-05
US60202274 2000-05-05
US26232101P 2001-01-17 2001-01-17
US60262321 2001-01-17
PCT/US2001/014508 WO2001085910A2 (en) 2000-05-05 2001-05-04 Agents that modulate dna-pk activity and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2001274817A1 true AU2001274817A1 (en) 2001-11-20

Family

ID=26897522

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001274817A Abandoned AU2001274817A1 (en) 2000-05-05 2001-05-04 Agents that modulate dna-pk activity and methods of use thereof

Country Status (3)

Country Link
US (2) US6893821B2 (en)
AU (1) AU2001274817A1 (en)
WO (1) WO2001085910A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1311288A1 (en) * 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
WO2004021243A2 (en) * 2002-08-09 2004-03-11 Siemens Aktiengesellschaft Method and computer program comprising program code means, and computer program product for analysing the activity of a pharmaceutical preparation
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5’ cpg nucleic acids and methods of use
US20050084890A1 (en) * 2003-10-07 2005-04-21 Turchi John J. High-throughput screening assay for inhibitors of replication protein A
US20060110390A1 (en) * 2004-08-25 2006-05-25 Myogen, Inc. Inhibition of Ku as a treatment for cardiovascular diseases
NZ561144A (en) * 2005-03-04 2009-09-25 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
CN101268101A (en) * 2005-07-07 2008-09-17 科利制药集团公司 Combination therapy of anti-CTLA-4 antibody and synthetic oligodeoxynucleotide containing CpG motif for cancer treatment
JP2009507848A (en) * 2005-09-09 2009-02-26 オレゴン ヘルス アンド サイエンス ユニバーシティ Neuroprotective drugs
US20100130425A1 (en) * 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
EP3983542A2 (en) 2019-06-17 2022-04-20 CRISPR Therapeutics AG Methods and compositions for improved homology directed repair
US20230095192A1 (en) * 2020-03-03 2023-03-30 University Of Washington Synthetic agonists of dna-pk and their use
EP4263829A1 (en) 2020-12-17 2023-10-25 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
WO2025181336A1 (en) 2024-03-01 2025-09-04 Cellectis Sa Compositions and methods for hbb-editing in hspc

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011275A2 (en) 1997-09-05 1999-03-11 The Regents Of The University Of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
WO1999033971A1 (en) 1997-12-31 1999-07-08 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
WO2000067023A1 (en) 1999-04-29 2000-11-09 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers

Also Published As

Publication number Publication date
WO2001085910A3 (en) 2002-04-04
US20030176373A1 (en) 2003-09-18
WO2001085910A2 (en) 2001-11-15
US6893821B2 (en) 2005-05-17
US20030125284A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
AU2001274817A1 (en) Agents that modulate dna-pk activity and methods of use thereof
AU2002211389A1 (en) Microfluidic devices and methods of use
AU6340600A (en) Telomerase inhibitors and methods of their use
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002314466A1 (en) Withasol and methods of use
AU3622600A (en) Metalloproteinases and methods of use therefor
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002230717A1 (en) Use of convergence-enabled dvd and web system
AU2002233608A1 (en) Modulation of gsk-3beta activity and its different uses
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
AU2001255521A1 (en) Biphasic reaction vessel and methods of use
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2001262939A1 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
AU2001296448A1 (en) Tumor marker and methods of use
AU2001284380A1 (en) Therapeutic and cosmetic uses of heparanases
AU3725500A (en) Hand-held bidet and method of use
AU1454199A (en) Pdgf-mediated microvascular communication and methods of use thereof
AU3863900A (en) Prolyl peptidases and methods of use
AUPQ760400A0 (en) Herbical formulations and methods of use thereof
AU4021700A (en) Methods of use of beta1-integrin inhibitors